Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
107.2 USD | -0.85% |
|
-4.90% | -12.88% |
06-20 | Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating | MT |
06-20 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.88% | 6.82B | |
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer